1-3 of 3
Sandra Fatima Gualandro
Close
Sort by
Journal Articles

Ravulizumab Provides Durable Control of Intravascular Hemolysis and Improves Survival in Patients with Paroxysmal Nocturnal Hemoglobinuria: Long-Term Follow-up of Study 301 and Comparisons with Patients of the International PNH Registry

Austin Kulasekararaj, Hubert Schrezenmeier, Kensuke Usuki, Aleksander Kulagin, Sandra Fatima Gualandro, Rosario Notaro, Masayo Ogawa, Ji Yu, Ami Patel, Yogesh Patel, Wolfgang Füreder, Regis Peffault De Latour, Jong-Wook Lee
Journal: Blood
Blood (2023) 142 (Supplement 1): 2714.
https://doi.org/10.1182/blood-2023-189150
Published: 2023
Journal Articles

Efficacy and Safety of Subcutaneous Ravulizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Received Prior Intravenous Eculizumab: 2-Year Follow-up

Caroline I Piatek, Flore Sicre De Fontbrune, Fahri Sahin, Wolfgang Füreder, Sandra Fatima Gualandro, Wilma Barcellini, Masayo Ogawa, Stephan Ortiz, Ayca Ozol-Godfrey, Jeff Szer, Mustafa Yenerel
Journal: Blood
Blood (2023) 142 (Supplement 1): 2713.
https://doi.org/10.1182/blood-2023-190060
Published: 2023
Journal Articles

NIH Bayesian Score As a Stratification Tool in Sickle Cell Disease - Results from a Single Center Cohort in Brazil

Guilherme Henrique Hencklain Fonseca, MD, Lutu Ima Viana da Graca, MD/ Resident, Rogerio Souza, MD PhD, Liliana Mitie Suganuma, MD, Vanderson Rocha, MD PhD, Sandra Fatima Gualandro, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2254.
https://doi.org/10.1182/blood.V130.Suppl_1.2254.2254
Published: 2017